Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma
Aim: This study assessed the cost–utility of mogamulizumab, a novel monoclonal antibody, versus established clinical management (ECM) in UK patients in previously treated advanced mycosis fungoides (MF)/S ´ ezary syndrome (SS). Materials & methods: Lifetime partitioned survival model based on...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-06-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |